1,012 results match your criteria patients oud


Neural mapping of anhedonia across psychiatric diagnoses: A transdiagnostic neuroimaging analysis.

Neuroimage Clin 2021 Sep 16;32:102825. Epub 2021 Sep 16.

University of Basel, Department of Psychiatry (UPK), Basel, Switzerland. Electronic address:

Anhedonia has been associated with abnormal reward-related striatal dopamine functioning in patients with different psychiatric disorders. Here, we tested whether anhedonia expression mapped onto striatal volume across several psychiatric diagnoses. T1-weighted images from 313 participants including 89 healthy controls (HC), 22 patients with opioid use disorder (OUD), 50 patients with major depressive disorder (MDD), 45 patients with borderline personality disorder (BPD), 49 patients with first-episode psychosis (FEP), 43 patients with cocaine use disorder (CUD) and 15 patients with schizophrenia (SZ) were included. Read More

View Article and Full-Text PDF
September 2021

An Exploratory Study of Sex and Gender Differences in Demographic, Psychosocial, Clinical, and Substance Use Treatment Characteristics of Patients in Outpatient Opioid Use Disorder Treatment with Buprenorphine.

Transl Issues Psychol Sci 2021 Jun 4;7(2):141-153. Epub 2021 Feb 4.

Department of Psychology, Virginia Commonwealth University.

As treatment expansion in the opioid epidemic continues, it is important to examine how the makeup of individuals with opioid use disorder (OUD) is evolving. Treatment programs are increasingly utilizing buprenorphine, an effective OUD medication. This exploratory study examines sex and gender differences in psychosocial, clinical and substance use treatment characteristics of a clinical population in outpatient medication treatment for OUD with buprenorphine. Read More

View Article and Full-Text PDF

Exploring the Interactions between Non-Medical Methamphetamine Use and Prescribed Buprenorphine or Naltrexone in Opioid Use Disorder Treatment Retention.

Subst Use Misuse 2021 Sep 20:1-11. Epub 2021 Sep 20.

Department of Psychiatry, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, USA.

Objectives: Our objectives were to examine the impact of methamphetamine use on opioid use disorder (OUD) treatment retention in patients prescribed either buprenorphine/buprenorphine-naloxone (BUP-NX) or naltrexone/extended-release naltrexone (XR-NTX), while also exploring the role of other risk factors that may modify the impact of methamphetamine use.

Methods: We conducted an exploratory retrospective study examining OUD treatment retention in 127 patients in Ohio (USA). Patients were prescribed either BUP-NX or naltrexone/XR-NTX. Read More

View Article and Full-Text PDF
September 2021

Critical illness in patients with metastatic cancer: a population-based cohort study of epidemiology and outcomes.

Authors:
Lavi Oud

J Investig Med 2021 Sep 17. Epub 2021 Sep 17.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Texas Tech University Health Sciences Center at the Permian Basin, Odessa, Texas, USA

The appropriateness of intensive care unit (ICU) admission of patients with metastatic cancer remains debated. We aimed to examine the short-term outcomes and their temporal pattern in critically ill patients with metastatic disease. We used state-wide data to identify hospitalizations aged ≥18 years with metastatic cancer admitted to ICU in Texas during 2010-2014. Read More

View Article and Full-Text PDF
September 2021

Reproducibility and responsiveness of the Frailty Index and Frailty Phenotype in older hospitalized patients.

BMC Geriatr 2021 Sep 17;21(1):499. Epub 2021 Sep 17.

Department of Internal Medicine and Geriatrics, University of Groningen, University Medical Center Groningen, PO Box 30001, HPC: AA43, 9700 RB, Groningen, The Netherlands.

Background: There is growing interest for interventions aiming at preventing frailty progression or even to reverse frailty in older people, yet it is still unclear which frailty instrument is most appropriate for measuring change scores over time to determine the effectiveness of interventions. The aim of this prospective cohort study was to determine reproducibility and responsiveness properties of the Frailty Index (FI) and Frailty Phenotype (FP) in acutely hospitalized medical patients aged 70 years and older.

Methods: Reproducibility was assessed by Intra-Class Correlation Coefficients (ICC), standard error of measurement (SEM) and smallest detectable change (SDC); Responsiveness was assessed by the standardized response mean (SRM), and area under the receiver operating characteristic curve (AUC). Read More

View Article and Full-Text PDF
September 2021

Optimizing opioid use disorder treatment with naltrexone or buprenorphine.

Drug Alcohol Depend 2021 Sep 11;228:109031. Epub 2021 Sep 11.

Department of Psychiatry, School of Medicine, Columbia University, and New York State Psychiatric Institute, New York, NY, United States.

Background: Relapse rates during opioid use disorder (OUD) treatment remain unacceptably high. It is possible that optimally matching patients with medication type would reduce risk of relapse. Our objective was to learn a rule by which to assign type of medication for OUD to reduce risk of relapse, and to estimate the extent to which risk of relapse would be reduced if such a rule were used. Read More

View Article and Full-Text PDF
September 2021

Opioid use disorder among hospitalized adults in North Carolina: Comparative analysis of national and statewide trends.

J Opioid Manag 2021 Jul-Aug;17(4):343-352

Graduate Program in Public Health, Eastern Virginia Medical School, Norfolk, Virginia.

Objective: Hospital resource utilization is reported to be higher among patients with opioid use disorder (OUD) compared with those without OUD at national and local levels. However, utilization of healthcare services associated with OUD in North Carolina (NC) has not been adequately characterized. We describe inpatient hospital resource utilization among adults with an OUD-diagnosed in NC and the United States (US). Read More

View Article and Full-Text PDF
September 2021

Comparison of naltrexone implant and oral buprenorphine-naloxone in the treatment of opiate use disorder.

Hum Psychopharmacol 2021 Sep 17:e2813. Epub 2021 Sep 17.

Department of Psychiatry, Akdeniz University Faculty of Medicine, Antalya, Turkey.

Objective: We aimed to compare the effectiveness of extended-release naltrexone (XR-NTX) implant and sublingual buprenorphine-naloxone (BUP-NX) in relapse prevention in opiate use disorder (OUD).

Methods: Medical records of 400 patients who were treated for OUD between 2016 and 2020 were retrospectively evaluated concerning sociodemographic and clinical characteristics and abstinence duration with either BUP-NX (192 patients) or XR-NTX (208 patients) as maintenance treatments.

Results: The median age of patients using BUP-NX was 25. Read More

View Article and Full-Text PDF
September 2021

Multivariate pattern analysis links drug use severity to distributed cortical hypoactivity during emotional inhibitory control in opioid use disorder.

Neuroimage Clin 2021 Aug 29;32:102806. Epub 2021 Aug 29.

Center for Studies of Addiction, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, 3535 Market St Ste 500, Philadelphia, PA 19104, USA.

Opioid use disorder (OUD) is characterized by emotional and cognitive impairements that are associated with poor treatment outcomes. The present study investigated the neural mechanism underlying emotion evaluation and inhibitory control using an affective go/no-go (AGN) task and its association with drug use severity and craving in patients with OUD. Twenty-six recently detoxified patients with OUD underwent functional magnetic resonance imaging (fMRI) while performing the AGN task that required response to frequently presented appetitive stimuli ("go") and inhibition of response to infrequently presented aversive stimuli ("no-go"). Read More

View Article and Full-Text PDF

Physical therapists should play a greater role in managing patients with opioid use and opioid misuse.

Subst Abus 2021 Sep 15:1-6. Epub 2021 Sep 15.

Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.

The U.S. opioid crisis necessitates that health care providers of all types work collaboratively to manage patients taking prescription opioid medications and manage those who may be misusing prescription opioids. Read More

View Article and Full-Text PDF
September 2021

Opioid treatment programs, telemedicine and COVID-19: A scoping review.

Subst Abus 2021 Sep 14:1-8. Epub 2021 Sep 14.

Department of Medical Informatics and Clinical Epidemiology, Pacific Northwest Evidence-Based Practice Center, Oregon Health & Science University, BICC, Portland, OR, USA.

Methadone and buprenorphine are effective medications for opioid use disorder (MOUD) that are highly regulated in the United States. The on-going opioid crisis, and more recently COVID-19, has prompted reconsideration of these restrictions in order to sustain and improve treatment access, with renewed interest in telemedicine. We reviewed the evidence on use of telemedicine interventions and applicability to MOUD policy changes in the post-COVID-19 treatment landscape. Read More

View Article and Full-Text PDF
September 2021

Rapid microinduction of sublingual buprenorphine from methadone in an outpatient setting: "A case series".

J Opioid Manag 2021 ;17(7):167-170

Department of Psychiatry and Behavioral Sciences, University of Kansas Health System, Kansas City, Kansas. ORCID: https://orcid.org/0000-0003-4209-591X.

Buprenorphine (BPN), FDA approved for opioid use disorder (OUD), requires an induction protocol for the patient in mild to moderate withdrawal. This can be problematic in outpatient practice due to complicated medical management. An emerging technique in literature uses a novel approach, called microinduction. Read More

View Article and Full-Text PDF
September 2021

Adverse effects of regulation on buprenorphine prescribing and its impact on the treatment of opioid use disorder.

J Opioid Manag 2021 ;17(7):133-139

Mercy Health - St Elizabeth - Youngstown Hospital, Youngstown, Ohio.

Problem: Drug addiction and misuse is a medical and societal problem that has exacted a heavy toll on the United States, and, indeed, the world. In the United States, opioids are currently the main driver of drug overdose deaths. Despite the proven safety and efficacy of medically assisted therapy (MAT) using buprenorphine for the treatment of opioid use disorder (OUD), as well as the fact that its use is regulated by US Federal Law, many states have enacted separate and often burdensome regulations that restrict the prescribing of buprenorphine beyond those required by the US Drug Enforcement Agency (DEA) under the provisions of the DATA 2000 Act, and unnecessarily reduce the availability of effective treatment of OUD in those states. Read More

View Article and Full-Text PDF
September 2021

Geographic analysis of military health system (MHS) buprenorphine prescribers and patients.

J Opioid Manag 2021 ;17(7):87-100

Georgetown University School of Medicine, Program Director Pain Fellowship, Walter Reed National Military Medical Center, Bethesda, Maryland.

Objective: To demonstrate the prevalence of opioid use disorder (OUD) in the military health system (MHS), geographically map OUD patients and providers, and offer policy recommendations to help increase buprenorphine waiver prescribing.

Design: This study was a retrospective review of data from the MHS records. Deidentified records of MHS OUD patients receiving buprenorphine were utilized. Read More

View Article and Full-Text PDF
September 2021

Patient satisfaction with clinic-based medication pick up: Addressing pharmacy-level challenges to buprenorphine access.

J Opioid Manag 2021 ;17(7):77-86

Cordant Health Solutions, Denver, Colorado.

Introduction: Pharmacy-level challenges that exist for patients when seeking to fill buprenorphine prescriptions at traditional retail pharmacies can result in a less than optimal treatment experience. High patient satisfaction with treatment for opioid use disorder (OUD), which for oral buprenorphine treatment includes the necessary step of obtaining medication after being prescribed, is associated with positive health outcomes and, therefore, is of great clinical interest. The objective of this study was to examine patient satisfaction when participating in a pharmacy program that coordinated buprenorphine delivery and provision to patients at office visits instead of requiring patients to fill their prescriptions at local pharmacies. Read More

View Article and Full-Text PDF
September 2021

A history of opioid abuse: Why buprenorphine is superior for the management of opioid use disorder and pain.

J Opioid Manag 2021 ;17(7):43-50

Pain Management Division, Westchester Medical Center, Valhalla, New York. ORCID: https://orcid.org/0000-0002-9030-2314.

Opioid abuse represents a public health crisis that has significant associated morbidity and mortality. Since beginning in the early 1990's, the opioid abuse epidemic has been difficult to control due to regulatory, economic, and psychosocial factors that have perpetuated its existence. This era of opioid abuse has been punctuated by three distinct rises in mortality, precipitated by unique public health problems that needed to be addressed. Read More

View Article and Full-Text PDF
September 2021

Use of telemedicine for opioid use disorder treatment - Perceptions and experiences of opioid use disorder clinicians.

Drug Alcohol Depend 2021 Aug 28;228:108999. Epub 2021 Aug 28.

Department of Health Care Policy, Harvard Medical School, 180A Longwood Avenue, Boston, MA, 02115, United States. Electronic address:

Objective: To understand clinician use of and opinions about telemedicine for opioid use disorder (tele-OUD) during the COVID-19 pandemic.

Methods: An electronic national survey was administered in fall 2020 to 602 OUD clinicians recruited from WebMD/Medscape's online panel. The survey completion rate was 97. Read More

View Article and Full-Text PDF

Causes of Death in the 12 months After Hospital Discharge Among Patients With Opioid Use Disorder.

J Addict Med 2021 Sep 10. Epub 2021 Sep 10.

Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR (CK); Department of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR (CK, RC, PTK, HE); Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, OR (CDM); Department of Medicine, Division of Hospital Medicine, Oregon Health & Science University, Portland, OR (HE).

Background: Patients with substance use disorders are seven times more likely hospitalized than the general population. However, causes of death for recently hospitalized patients with Opioid Use Disorder (OUD) are not well described. This study describes causes of death in the year post-discharge among hospitalized patients with OUD. Read More

View Article and Full-Text PDF
September 2021

A Low-threshold Comprehensive Shared Medical Appointment Program for Perinatal Substance Use in an Underserved Population.

J Addict Med 2021 Sep 10. Epub 2021 Sep 10.

Cooper University Health Care, Center for Healing, Division of Addiction Medicine, Camden, NJ (VSG, JH, IJ, BR, LW, MS, KEB), Cooper Medical School of Rowan University, Camden, NJ (BY, KH, KEB), Cooper University Health Care, Cooper Research Institute, Camden, NJ (KH), Department of Emergency Medicine, Division of Addiction Medicine and Medical Toxicology, Cooper University Health Care, Camden, NJ (MS).

Objectives: We describe retention in care, medication for opioid use disorder (MOUD) prescribing, and urine toxicology outcomes of a comprehensive perinatal shared medical appointment model that combined medication, group-based counseling, and recovery supports.

Methods: We conducted a retrospective study of program retention between 11/1/16 and 3/31/20 in pregnant and postpartum women with substance dependence or use disorder. Disengagement reasons, MOUD prescribing, and urine toxicology were abstracted from medical records. Read More

View Article and Full-Text PDF
September 2021

Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence.

Drug Alcohol Depend 2021 Jul 29;228:108923. Epub 2021 Jul 29.

Center to Improve Veteran Involvement in Care, VA Portland Health Care System, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, United States; Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, United States. Electronic address:

Background: A growing body of research has examined adjunctive interventions supportive of engagement and retention in treatment among patients receiving buprenorphine for opioid use disorder (OUD). We conducted a systematic review of the literature addressing the effect on key outcomes of adjunctive interventions provided alongside standard medical management of buprenorphine in outpatient settings.

Methods: We included prospective studies examining adults receiving buprenorphine paired with an adjunctive intervention for the treatment of OUD in an outpatient setting. Read More

View Article and Full-Text PDF

Designing and validating a Markov model for hospital-based addiction consult service impact on 12-month drug and non-drug related mortality.

PLoS One 2021 10;16(9):e0256793. Epub 2021 Sep 10.

Department of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, United States of America.

Introduction: Addiction consult services (ACS) engage hospitalized patients with opioid use disorder (OUD) in care and help meet their goals for substance use treatment. Little is known about how ACS affect mortality for patients with OUD. The objective of this study was to design and validate a model that estimates the impact of ACS care on 12-month mortality among hospitalized patients with OUD. Read More

View Article and Full-Text PDF
September 2021

Characteristic changes in EEG spectral powers of patients with opioid-use disorder as compared with those with methamphetamine- and alcohol-use disorders.

PLoS One 2021 10;16(9):e0248794. Epub 2021 Sep 10.

Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, United States of America.

Electroencephalography (EEG) likely reflects activity of cortical neurocircuits, making it an insightful estimation for mental health in patients with substance use disorder (SUD). EEG signals are recorded as sinusoidal waves, containing spectral amplitudes across several frequency bands with high spatio-temporal resolution. Prior work on EEG signal analysis has been made mainly at individual electrodes. Read More

View Article and Full-Text PDF
September 2021

Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database.

JAMA Netw Open 2021 Sep 1;4(9):e2123019. Epub 2021 Sep 1.

Millennium Health, San Diego, California.

Importance: Polysubstance use is a concern for patients treated for opioid use disorder (OUD). While buprenorphine can curtail harmful opioid use, co-occurring use of nonprescribed substances, such as cocaine, methamphetamine, and other opioids, may negatively affect treatment outcomes.

Objective: To characterize factors associated with urine drug positivity for nonprescribed substances among patients prescribed buprenorphine. Read More

View Article and Full-Text PDF
September 2021

Prehospital Initiation of Buprenorphine Treatment for Opioid Use Disorder by Paramedics.

Prehosp Emerg Care 2021 Sep 10:1-6. Epub 2021 Sep 10.

Alameda Health System, Highland Hospital, Emergency Medicine, Oakland, CA.

Prehospital initiation of buprenorphine treatment for Opioid Use Disorder (OUD) by paramedics is an emerging potential intervention. Many patients who may be at high risk for overdose deaths may never engage in treatment because they frequently refuse transport. Recent data have demonstrated a significant increase in both short and long term mortality following an opioid overdose. Read More

View Article and Full-Text PDF
September 2021

Adapting behavioural interventions to compensate for cognitive dysfunction in persons with opioid use disorder.

Gen Psychiatr 2021 16;34(4):e100412. Epub 2021 Aug 16.

Allied Health Sciences, University of Connecticut, Storrs, Connecticut, USA.

Treatment for opioid use disorder (OUD) is often in the context of biobehavioural interventions, consisting of medication for OUD (for example, methadone and buprenorphine), which is accompanied by psychoeducation and/or behavioural therapies. Patients with OUD often display weaknesses in cognitive function that may impact the efficacy of such behavioural interventions. A review of the literature was conducted to: (1) describe common cognitive dysfunction profiles among patients with OUD, (2) outline intervention approaches for patients with OUD, (3) consider the cognitive demands that interventions place on patients with OUD and (4) identify potential accommodation strategies that may be used to optimise treatment outcomes. Read More

View Article and Full-Text PDF

Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV.

AIDS Behav 2021 Sep 8. Epub 2021 Sep 8.

Center for Research on Health Care, Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Although opioid agonist therapy (OAT) is associated with positive health outcomes, including improved HIV management, long-term retention in OAT remains low among patients with opioid use disorder (OUD). Using data from the Veterans Aging Cohort Study (VACS), we identify variables independently associated with OAT retention overall and by HIV status. Among 7,334 patients with OUD, 13. Read More

View Article and Full-Text PDF
September 2021

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail.

JAMA Netw Open 2021 Sep 1;4(9):e2123032. Epub 2021 Sep 1.

Department of Medicine, New York University Grossman School of Medicine, New York.

Importance: Extended-release buprenorphine (XRB), a monthly injectable long-acting opioid use disorder (OUD) treatment, has not been studied for use in corrections facilities.

Objective: To compare treatment retention following release from jail among adults receiving daily sublingual buprenorphine-naloxone (SLB) vs those receiving XRB.

Design, Setting, And Participants: This open-label, randomized comparative effectiveness study included 52 incarcerated adults in New York City observed for 8 weeks postrelease between June 2019 and May 2020. Read More

View Article and Full-Text PDF
September 2021

Clinical leaders and providers' perspectives on delivering medications for the treatment of opioid use disorder in Veteran Affairs' facilities.

Addict Sci Clin Pract 2021 09 6;16(1):55. Epub 2021 Sep 6.

Health Services Research & Development (HSR&D) Seattle Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs (VA) Puget Sound Health Care System, Seattle, WA, USA.

Background: Improving access to medication treatment of opioid use disorder (MOUD) is a national priority, yet common modifiable barriers (e.g., limited provider knowledge, negative beliefs about MOUD) often challenge implementation of MOUD delivery. Read More

View Article and Full-Text PDF
September 2021

Analysis of genetic and clinical factors associated with buprenorphine response.

Drug Alcohol Depend 2021 Aug 28;227:109013. Epub 2021 Aug 28.

Mental Illness Research, Education and Clinical Center, Crescenz Veterans Affairs Medical Center, Philadelphia, PA 19104, United States; Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, United States. Electronic address:

Background: Buprenorphine, approved for treating opioid use disorder (OUD), is not equally efficacious for all patients. Candidate gene studies have shown limited success in identifying genetic moderators of buprenorphine treatment response.

Methods: We studied 1616 European-ancestry individuals enrolled in the Million Veteran Program, of whom 1609 had an ICD-9/10 code consistent with OUD, a 180-day buprenorphine treatment exposure, and genome-wide genotype data. Read More

View Article and Full-Text PDF

Tele-buprenorphine for emergency department overdose visit follow up and treatment initiation.

Am J Emerg Med 2021 Aug 28;50:409-412. Epub 2021 Aug 28.

Department of Emergency Medicine, The Warren Alpert Medical School of Brown University, 55 Claverick St, Providence, RI 02903, United States of America.

Introduction: An ED visit for opioid overdose may be a person's only contact with the medical and behavioral health care systems and is an important opportunity to reduce risk of subsequent overdose and death. While ED initiatives to engage people with opioid use disorder (OUD) are being increasingly implemented, there are significant gaps in the receipt of services at the time of the ED encounter.

Methods: This is a retrospective cohort study of an outreach pilot project providing real-time telehealth delivered buprenorphine initiation and referral to community harm reduction and addiction treatment services via a follow up telephone call to patients after an ED visit for an opioid overdose. Read More

View Article and Full-Text PDF